Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific Plc LSE:NSCI London Ordinary Share GB00BN4R5Q82 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -4.00 -3.36% 115.00 192,147 16:09:11
Bid Price Offer Price High Price Low Price Open Price
114.00 116.00 119.00 115.00 119.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.39 -2.38 -2.90 17
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:26 O 589 116.00 GBX

Netscientific (NSCI) Latest News

More Netscientific News
Netscientific Investors    Netscientific Takeover Rumours

Netscientific (NSCI) Discussions and Chat

Netscientific Forums and Chat

Date Time Title Posts
19/6/202114:56NetScientific PLC3,552

Add a New Thread

Netscientific (NSCI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Netscientific trades in real-time

Netscientific (NSCI) Top Chat Posts

Netscientific Daily Update: Netscientific Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker NSCI. The last closing price for Netscientific was 119p.
Netscientific Plc has a 4 week average price of 58.80p and a 12 week average price of 49.50p.
The 1 year high share price is 209p while the 1 year low share price is currently 4.60p.
There are currently 15,017,188 shares in issue and the average daily traded volume is 523,827 shares. The market capitalisation of Netscientific Plc is £17,269,766.20.
kalkaar: update from WH Ireland analysts: NetScientific (NSCI) – Corporate – PDS Biotech – announced public offering after hours Market Cap £17.7m (£24.8m1 enlarged share capital) Share Price 118p NetScientific, the international life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has itself announced (after trading hours 14 June) that it is commencing an underwritten public offering of shares of its common stock. PDS intends to use a portion of the net proceeds for the development of its clinical pipeline and the balance for general corporate / working capital purposes. No further details were released with respect to size and pricing. PDS Biotech’s shares fell 19% in afterhours trading to $10.41 (from $12.86), in response to the announcement, and we would anticipate a further update from PDS in the next 24-48 hours. PDS’s last placing was in August 2020, raising $16.5m at a price of $2.75 through the issue of 6m shares. WHI View: NetScientific currently retains a 5.75% stake in PDS Biotechnology and has hitherto supported such placings, albeit typically diluted as part of the process. Our last SOTP fair value estimate for NSCI was 162p, with PDS captured at a price of $11.4 (09/06/21) – unrisked value of £10.4m. PDS has demonstrated significant progress in recent months, which has been mirrored in its valuation – with the share price increasing eight fold over the last twelve months. The company is clearly capitalising on this strength as it seeks to develop further its pipeline and to support clinical trials currently in place. NSCI’s CEO, Dr Ilian Iliev, is on PDS’s board.
kalkaar: revised broker note this am: WHI View: The success of the placing further illustrates the momentum NSCI is seeing under a rejuvenated strategy and strengthened management team. Our updated risked-based SOTP analysis implies fair value of 162p per share (assuming a revised 21m shares in issue), the recapitalised and strengthened balance sheet reducing the risk profile of the Group and the PDS holding (NASDAQ:PDSB) increasing in value by 36% since our re-initiation on 25 May. A number of potential catalysts exist that could yield significant value inflection points for NSCI. NSCI’s unrisked holding in PDS Biotech2 (5.75%) alone has a realisable value of £10.4m, 37% of the NSCI’s market capitalisation (based on the enlarged share capital).
blakieboy7: TIDMNSCIRNS Number : 5243BNetScientific PLC10 June 2021THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR A SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY SUCH OFFER, SOLICITATION OR COMMITMENT WHATSOEVER IN ANY OF THOSE JURISDICTIONS.NetScientific PLC("NetScientific" or the "Company")Result of Placing and Total Voting RightsNetScientific, the life sciences and sustainability technology investment and commercialisation group, is pleased to announce that it has raised gross proceeds of approximately GBP7.7 million in an oversubscribed fundraising as announced earlier today (the "Placing").A total of 5,958,123 Placing Shares in the Company have been conditionally placed by WH Ireland Limited ("WH Ireland") with new and existing investors at a price of 130 pence per share (the "Issue Price").Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and it is anticipated that dealings in the Placing Shares will commence on AIM at 8.00 a.m. on 29 June 2021 ("Admission"). The Placing Shares will represent approximately 28.4 per cent. of the Company's issued share capital following completion of the Placing ("Enlarged Share Capital"). The Issue Price represents a discount of approximately 10.3 per cent. to the closing mid-market price of NetScientific's existing ordinary shares of 145 pence on 9 June 2021 (being the last business day prior to the announcement of the Placing earlier today).The Placing is subject to, inter alia, shareholder approval, Admission becoming effective and the Placing Agreement becoming unconditional and not being terminated in accordance with its terms.The Company expects to publish a circular in connection with the Placing, in due course, which will contain a notice convening the General Meeting in order to approve certain matters necessary to implement the Fundraising.A copy of the Circular will be made available on the Company's website to the unpredictability of the UK Government guidance and continuing potential health risks posed by COVID-19, it appears to the Directors that significant restrictions on personal movement may still be in place on the date of the General Meeting. Accordingly, the Company will hold the General Meeting with the minimum attendance required to form a quorum and the Directors strongly encourage all Shareholders to vote on the Resolutions by proxy or online. Any Shareholders seeking to attend the General Meeting in person will be refused entry.The actions that Shareholders should take to vote on the Resolutions will be set out in the Circular to be posted in due course, along with the recommendations of the Directors.Following Admission, the Company's issued and fully paid share capital will consist of 20,975,311 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. The figure of 20,975,311 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.Capitalised terms used but not defined in this announcement have the meanings given to them in the Company's announcement released earlier today in respect of the Placing unless the context provides otherwise.John Clarkson, Executive Chairman, stated: "After a year of tremendous progress, with the turnaround and transformation of the business, the company is now well set for the future. We are delighted to have the support of existing shareholders and welcome new investors in this successful placing, which reinforces and further enhances the business prospects. The NetScientific board thanks everyone for their contribution to this ongoing success."Ilian Iliev , Chief Executive Officer added: "NetScientific is well positioned to drive its growth plans, support a balanced and expanding portfolio, and pursue attractive trans-Atlantic opportunities in the healthcare and sustainability sectors in a post-COVID environment. We're delighted to welcome the support of a new institutional investor and the strong investor support in this placement provides further impetus behind our model of 'capital-light' investment combined with pro-active management and value added support to our portfolio."
shanew48: There seems to be genuine potential for the share price to multiply by many many times over a short period of time here so it's not going to matter too much if you pay £1, £2 £3 or £5 per share if the share price is destined to be in the £20-£50 + range in the future.
shanew48: I believe the NSCI share price was £20 + not that long ago prior to the Woodford fallout?, surely after the recent news and there only being 15 mill shares in issue, £20 + should be achievable again!
the stigologist: Today's news from NSCI re marketing an Astra Zeneca SARS-COV2 test is exciting but should be just the start ProAxsis the portfolio Company involved in this deal is 95% owned by NSCI but only accounted for £3.5m of the c.£30m NAV NSCI Share Price @ 100p with 15m shares outstanding gives a Market Cap of £15m vs NAV of 200p+ (£30m+) ! So despite this morning's 50% rise you can still get into NSCI 'cheap' Furthermore NSCI's two big investments PDSB and Glycotest are both due to report potential value inflection point news in next 1 month PDS Biotech (NASDAQ : PDSB) has 3 Presentations scheduled in next 2 weeks 1. June 7th at ASCO Cancer Research Conference 2. June 8th Conf Call with analysts re ASCO Presentation 3. June 16th Investor Day featuring presentations from 3 US Government Scientists ! Glycotest is a Liver Cancer test currently in clinical trials of which NSCI own 50% with 40% owned by Chinese conglomerate Fosun (also owners of Wolves, Thomas Cook, Chinese partners for Pfizer/BioNTech vaccine). Liver Cancer test market is a $1bn+ opportunity. 2 Principals (CEO and 1 other shareholder) own 60% of NSCI so it's very tightly held How many Biotechs do you know where 3 US Government Scientists from the National Cancer Institute present on behalf of your collaboration ?!
bertiebingo: PDSB now 104% of NSCI mkt cap. Even if PDSB was to fall eg 30%, the NSCI stub is still very undervalued. For what its worth, WH Ireland estimated group worth £20m with PDSB £6.3m (market value now £11m) so stub £14m (currently valued approx £0m). If PDSB fails phase 3, then NSCI is just worth the Stub value which could be £5-14m vs NSCI mkt cap £11m. Does suggest that for now until phase 3 NSCI is very undervalued & the mkt cap should rise to £16-25m (assuming PDSB stays here) vs £11m now.
bertiebingo: PDSB is currently 73% of NSCI mkt cap. In April the Non-PDSB was approx £4m & approx 50% of NSCI but now 27%. Non-PDSB is now £2.5m when you could argue the move in PDSB adds value/solvency to the whole group. If you assume non-PDSB is £4m, and PDSB holding is now £6.7m then NSCI is worth £10.7m +17%. Infact in Q4 20 PDSB was 25-30% of NSCI, therefore the non-PDSB was £6-8m. Each £1m being worth approx 10% to NSCI share price therefore if non-PDSB is worth £7m, the shares need to increase by 50%. All this isnt including the acquisition effects etc etc.
loafofbread: With today's close, PDSB is pretty much our market cap and we have another £14M of assets. Insane volume so our 1,282,000 shares nice and liquid. NSCI Share price 52p, NAV £1.50. A repost of my Feb 1st note. If you have a look at the results and placing docs you come up with a slightly better NAV than the current share price A lot will depend on PDSB, but as we stand this evening. A couple of things to remember. Only 15M shares in issue Recent placing at 65p to buy EMV Capital. Concert party hold more than 50% of the shares so limited free float if it starts to move. EMV Capital portfolio £3.4M Cash £1.5M 3 main holdings £1.1M (Cyto,Edibone,G-Tech) Glycotest £5.0M (more now as we hold a higher %) PDSB £3.25M @ $3.00 a share. £14.25M I can't find a value for Proaxis, 100% owned, but as it just won a £300K grant and has new sales deals for USA and a few other areas, lets say £3M. Add in todays PDSB rise, which is another £650K and you get close to £18M. M Cap today less than £7M. PDSB has some near term news flow due over the next few months which could send it parabolic. Discuss!
kingston78: Consolidation of shares is usually a prelude to a disaster to the share price. The reverse is also true to bonus (split) shares. A strong company will have a high share price to the extent that investors find it difficult to buy in any meaningful quantity (this is psychological) so the company splits the shares say, from 1 to 10 shares (same value), but as there is pent up demand the share price after the split continues to go up. Unfortunately NetScientific consolidated its shares to make it look more respectable, but to no avail.
Netscientific share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 16:12:25